Several other equities analysts have also weighed in on the stock. Stifel Nicolaus set a $47.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a report on Friday, September 6th. Stephens set a $48.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a report on Monday, September 30th. Leerink Swann set a $50.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a report on Wednesday, July 31st. Barclays reiterated an “overweight” rating and set a $48.00 price objective on shares of Boston Scientific in a report on Tuesday, September 3rd. Finally, Piper Jaffray Companies set a $50.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a report on Wednesday, July 24th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $47.07.
BSX stock traded down $0.21 during midday trading on Friday, hitting $40.51. The stock had a trading volume of 3,199,353 shares, compared to its average volume of 7,209,796. The firm has a market cap of $56.54 billion, a P/E ratio of 27.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.76. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 0.81. Boston Scientific has a 1-year low of $31.56 and a 1-year high of $43.84. The business has a fifty day moving average price of $40.34 and a two-hundred day moving average price of $40.64.
In other news, SVP Maulik Nanavaty sold 9,623 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.66, for a total transaction of $400,894.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John Bradley Sorenson sold 6,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $42.79, for a total transaction of $256,740.00. Following the sale, the senior vice president now directly owns 42,385 shares of the company’s stock, valued at $1,813,654.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 101,072 shares of company stock valued at $4,188,092. 0.66% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the company. Alps Advisors Inc. grew its position in Boston Scientific by 12.2% in the 2nd quarter. Alps Advisors Inc. now owns 17,230 shares of the medical equipment provider’s stock worth $741,000 after purchasing an additional 1,874 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Boston Scientific by 2.2% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,654,915 shares of the medical equipment provider’s stock worth $243,049,000 after purchasing an additional 119,294 shares in the last quarter. North Star Investment Management Corp. bought a new stake in Boston Scientific in the 3rd quarter worth about $89,000. Cullen Frost Bankers Inc. grew its position in Boston Scientific by 28.7% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 407,826 shares of the medical equipment provider’s stock worth $17,528,000 after purchasing an additional 90,900 shares in the last quarter. Finally, MidWestOne Financial Group Inc. bought a new stake in Boston Scientific in the 2nd quarter worth about $444,000. 91.64% of the stock is owned by institutional investors.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Read More: What is a capital gain?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.